Navigation Links
Micromet Announces Public Offering of Common Stock
Date:7/29/2009

BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole book running manager, with RBC Capital Markets as co-manager in this offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on June 19, 2009, which became effective on July 2, 2009. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
2. Micromet Added to Russell 3000 Index
3. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
4. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
5. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
6. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
7. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
8. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
9. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
10. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
11. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...er 30, 2009 An international team of applied scie...Zrich have demonstrated compact, multibeam, and mu...rt of the light spectrum (infrared). By contrast, ...defined wavelength. The innovative multibeam laser...mote chemical sensing pollution monitoring, optica...
(Date:11/30/2009)...F MANOR, N.Y., Nov. 30 Good Public...or the publication of company-sponsored medical re...tish Medical Journal (BMJ). "The publication of GP...of providing support and guidance for industry spo...ts in the peer-reviewed medical literature," said ...
(Date:11/30/2009)...Nov. 30 BioMarin Pharmac... the Food and Drug Administration (FDA) has grante...(3,4-DAP), amifampridine phosphate, for the rare a...e (LEMS). 3,4-DAP has previously received orphan ...9, the Committee for Medicinal Products for Human ...
(Date:11/30/2009)...NDON, November 30 ApaTech, the rap...ope,s fastest growing,Biotech/Pharmaceutical/Medic...09 Technology Fast 500 for EMEA (Europe, Middle Ea...based on a companies, five-year revenue growth,fo... this period. This,achievement places ApaTech 9th ...
Breaking Biology Technology:Scientists demonstrate multibeam, multi-functional lasers 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4
...7 The market for congestive heart,failure (CHF) d...7, and is,expected to reach $30 billion by 2017, a...Congestive Heart Failure: Major World Markets, Vol...driven by three factors: an,increased incidence of...n,search of targeted therapies which is creating o...
...ril 17 Spherix Incorporated,(Nasdaq: SPEX ) anno...perations. Mr. Brown will be monitoring and overse...rial regarding the use of Naturlose(R) as a,treatm...as allowed Spherix,to terminate its agreement with...r full control of the clinical trial and its pivot...
...7 SPO Medical Inc. (OTC:,SPOM), a leading develop...r,use in portable monitoring devices, today announ...Capital Ventures (ACV), a leading provider of,comp... cap community, as an,investor relations consultan...ve Officer of SPO Medical,commented, "As we contin...
Other Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Spherix Hires Key Employees 2SPO Medical Retains American Capital Ventures for Investor Relations Services 2SPO Medical Retains American Capital Ventures for Investor Relations Services 3
(Date:11/26/2009)...ies has shown that closing schools in the event of...ficant role in reducing illness transmission. Rese...fectious Diseases compared opportunities for infe...g that they were reduced when schools are shut. ,...Belgium, led a team of European researchers in usi...
(Date:11/25/2009)...ay be used to boost resistance to, or slow, the de...edicine researchers report in a study published in..., Parkinson,s disease is caused by a degeneratio...nown as the substantia nigra, which is responsible...opamine in late-stage Parkinson,s causes symptoms ...
(Date:11/25/2009)...s some 250 million liters of blood through the bod...he heart have to be extremely durable. The researc...ir of the Department of Medicine III at Heidelberg...tus), has discovered a protein that is responsible...the sarcomere. In cooperation with other researche...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 1Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 9GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 1GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 2GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 3Opto electronic nose sniffs out toxic gases 9902 1Opto electronic nose sniffs out toxic gases 9902 2Opto electronic nose sniffs out toxic gases 9902 3
...ghting like a girl or fighting like a boy is hardw...in the Nov. 19 Nature Neuroscience advance online ...l School and the Institute of Molecular Pathology ...s "fruitless" is a key factor underlying sexual di...ne in an unlikely new animal model for understandi...
...e Shoklo Malaria Research Unit (SMRU), Thailand, w...28 December entitled "Twenty Years of Malaria Rese...nationally-renowned experts and featuring talks an...a, from epidemiology to therapeutics and from immu...Research Unit (SMRU) in Mae Sot, Thailand, which b...
...searchers at the Albert Einstein College of Medici...n grant from the National Cancer Institute to stud...t with surrounding tissues, cells and chemicals in... invade other areas of the body in the process kno...ohn Condeelis, co-chair of anatomy and structural ...
Other Biology News:Fighting like a girl or boy determined by gene in fruit flies 2Fighting like a girl or boy determined by gene in fruit flies 3Twenty Years of Malaria Research: Outcomes and Perspectives 2World's smallest cancer detection device 2
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
...r routine procedures. Hollandes contains formaldeh...l decalcify small bone specimens. Tissue that is f...ith most stains, and the cupric acetate in the sol...nophil and endocrine cell granules so that less ly...
...tograph/Mass Spectrometer, utilizing many of the h...igh throughput and excellent productivity, providi...io. Like the GCMS-QP2010 Plus, the GCMS-QP2010s fe...um separation, 20 temperature ramps, and both scan...
Biology Products: